• KSBB Journal
• /
• v.9 no.2
• /
• pp.165-173
• /
• 1994

In this paper we have described the structural characterization of recombinant bovine somatotropin produced in Escherichia coli. Recombinant bovine somatotropin consists of 191 amino acid residues with a calculated molecular weight of 21,802 Da. For fragmentation of recombinant bovine somatotropin, we have used trypsin, Staphylococcus aureus V8 pretease, CNBr, and mild acid hydrolysis method. Digestion and cleavage with these proteases and chemicals yielded peptides of various size for amino acid sequence determination. The N-terminal sequence analysis was carried out up to thirty residues. Because the design of the recombinant bovine somatotropin gene for expression was such that the coding sequence begins with an initiation codon, AUG, before Ala, the first amino acid of bovine somatotropin, we could expect the initial amino acid as N-formyl Met. But the first amino acid of this protein, expressed in E. coli cells as inclusion bodies, was Ala. And the amino acid composition of RP-HPLC purified recombinant bovine somatotropin was determined and no essencial difference was observed. The amino acid sequence of the recombinant bovine somatotropin was identical to that predicted from its recombinant gene. There was no processing or replacement of amino acid residues in recombinant bovine somatotropin expressed in E. coli. The hydropathy plot of recombinant bovine somatotropin revealed a hydrophobic region at the NH2-terminus and hydrophilic region at the COOH-terminus. The E. coli expression system is thought to be valuable for the expression of recombinant bovine somatotropin because protein was processed to remove the N-terminal Met residue by methionyl-aminopeptidase autonomously.

• Korean Journal of Veterinary Research
• /
• v.49 no.1
• /
• pp.9-15
• /
• 2009

The present study was carried out to examine the sustained release effect of the implantable bovine somatotropin (SRI-BST) formula. In the blood profile test in steers, the bovine somatotropin concentration in serum by radioimmunoassay showed the peak concentration on the first day after the implantation of the SRI-BST formula, and concentration proceeded for 5 days (p < 0.05). The insulin-like growth factor-1 concentration showed the peak concentration on the seventh day after implantation of the SRIF-BST formula, and concentration proceeded for 10 days (p < 0.05). The glucose showed the peak concentration on the first day after implantation of the SRI-BST formula, and concentration continued for 3 days (p < 0.05). The blood urea nitrogen showed the lowest concentration on the third day after implantation of the SRI-BST formula, and concentration continued for 7 days (p < 0.05). These results proved that the SRIF-BST formula was the sustained release effects in steers.

• Journal of Food Hygiene and Safety
• /
• v.10 no.2
• /
• pp.61-64
• /
• 1995

The present study was conducted to examine the effect of recombinant bovine somatotrpin(${\gamma}$BST), which was administered to cow to promote milk production, on bST levels in milk. Fourteen cows were divided cows were divided into two groups: 1) control cows received neither ${\gamma}$bST nor vehicle, 2) treated cows were administered twice at two-week interval with 500 mg ${\gamma}$bST each cow byj after lst injection. Milk samples were taken on day 0 (prior to injection), day 7 (7 days after lst injection), day 21 (7 days after 2nd injection) and day 35 (21 days after 2nd injection). Milk bST concentration was measured by the radioimmunoassay method. There was no statistical difference(p<0.05) in milk bST levels between two groups showing bST levels in the range of 1.8 ng/m/ to 3.1 ng/m/. That is, ${\gamma}$bST administration did not increase bST levels in milk.

• Korean Journal of Veterinary Research
• /
• v.48 no.1
• /
• pp.27-32
• /
• 2008

The present study was carried out to develop a sustained release implantable formula of bovine somatotropin (SRIF-BST) and to examine its sustained release effect. The SRIF-BST was produced by coating a solid pellet, which was comprised of BST and an excipient, made of a biodegradable polymer and poloxamer, which are capable of regulating the rate of BST release. The coated membrane of SRIFBST was observed with a field emission scanning electron microscope. The thickness of the coated membrane was approximately $1{\mu}m$, and the pore sizes of the coated membrane surface were below $10{\mu}m$. In dissolution test, the release duration of the SRIF-BST maintained for 10 days, whereas the release duration of the control BST formula maintained for 3 days. In weight gain assay and tibia test of hypophysectomized rats, the release duration of the SRIF-BST treated group was 12 days and the net weight gain was 53.16 g, also the tibia length and strength of the SRIF-BST treated group was increased 10.5% and 23.1% compared with those of the control group, respectively.

• Asian-Australasian Journal of Animal Sciences
• /
• v.2 no.3
• /
• pp.149-150
• /
• 1989

• Asian-Australasian Journal of Animal Sciences
• /
• v.2 no.3
• /
• pp.497-498
• /
• 1989

• Korean Journal of Veterinary Research
• /
• v.51 no.1
• /
• pp.1-6
• /
• 2011

Sixteen steers were used to investigate the efficacy of the sustained-release implant of bovine somatotropin (bST) in improving growth and feed:gain ratio during 12 weeks. Administration of the 400 mg bST implant resulted in a 16.1% increase in growth rate, and this increase was significant (p<.05). The use of the sustained-release implant did not alter (p>.05) feed intake and feed:gain ratio. Thirty-four cows were used to investigate the efficacy of the sustained-release implant of bST in milk production during 4 weeks. Administration of the 200 mg bST implant resulted in an 8.7% increase in milk production, and this increase was significant (p<.05). Twenty-four barrows were used to investigate the efficacy of the sustained-release implant of porcine somatotropin (pST) in improving growth, feed:gain ratio and backfat thickness during 6 weeks. Administration of the 120 mg pST implant resulted in a 11.4% increase in feed:gain ratio and a 60% decrease in backfat thickness, and these results were significant (p<.05). But the use of the sustained-release implant did not alter (p>.05) growth rate and feed intake.

• Asian-Australasian Journal of Animal Sciences
• /
• v.6 no.2
• /
• pp.211-218
• /
• 1993

The effect of active immunization against porcine somatostatin (SRIF-14) on somatostation and somatotropin secretion profile in 18 gilts was investigated. Gilts were assigned to the following treatments: control (sham injection, n = 6); bovine serum albumin (BSA) (injection of BSA with bacterial protein adjuvant, n = 6); SRIF (injection of BSA-SRIF-14 conjugate with bacterial protein adjuvant n = 6). Serum SRIF and pST were assayed from the blood samples taken on day 7 after the last immunization injection. Anti-SRIF antibody titres were assayed in weekly samples two weeks after the initial immunization to one week after the last immunization. Results revealed that the immunization protocol used in the present investigation failed to produce antibodies capable of neutralizing endogenous somatostatin. In addition, the porcine somatotropin assay revealed no significant differences in baseline pST concentration, mean peak amplitude and number of peaks during a 24 h secretory period among SRIF, BSA and control treatment. There were also no differences in SRIF baseline concentration, peak amplitude, and number of peaks during a 24 h secretory period among any of the three treatments. Circulating concentrations of pST and pSRIF were highly correlated (r = -0.09). Furthermore, anti-SRIF antibody titre was not detected in the serum of the gilts actively immunized against SRIF. These data, collectively, suggest that the protocol employed in the present investigation for active immunization against SRIF is not an effective method for changing SRIF and pST secretion profiles of the gilt and thus to enhance performance.

• Asian-Australasian Journal of Animal Sciences
• /
• v.3 no.3
• /
• pp.247-252
• /
• 1990

Nine Holstein cows in mid lactation period were utilized to examine the effect of recombinant bovine somatotropin (BST) of tow companies (Company A, Company B) on milk production and milk composition under the feeding conditions of Korea. Treatments were 0 (Control), 25 mg BST/day from company A (BST A) and 25 mg BST/day from company B (BST B) injected subcutaneously, once daily beginning at $200{\pm}20$ days postpartum and continuing for 28 days. Cows were fed ad libitum a total mixed diet throughout the experimental period. BST treatments increased average 4% fat corrected milk yields and milk energy output over the 28-day treatment period. However, no differences were observed in dry matter intake, gross efficiency, energy intake and percent milk energy. Although there was a tendency for increased milk fat percent, there were no differences in milk composition and yields of major milk components except for milk fat yield with BST injection. Somatic cells of all groups were also characteristic of a well managed herd. Neither mean body condition score nor body weight was significantly (p <0.05) changed before and during BST treatment. BST concentration in milk remained in the range of control animals throughout the experimental period of BST treatment. Results indicate that short-term injection of recombinant bovine somatotropin from two companies to lactating dairy cow resulted in similar increased in milk yield without alteration of major milk components or feed intake.

• Asian-Australasian Journal of Animal Sciences
• /
• v.2 no.3
• /
• pp.228-230
• /
• 1989